US 12,005,061 B2
Ophthalmic formulations of methotrexate
Dean Eliott, Carlsbad, CA (US); Pramod Sarpotdar, Roseville, CA (US); Stephen Gitu Machatha, Wilmington, MA (US); and Tomasz Stryjewski, Somerville, MA (US)
Assigned to Aldeyra Therapeutics, Inc., Lexington, MA (US)
Filed by Aldeyra Therapeutics, Inc., Lexington, MA (US)
Filed on Sep. 15, 2022, as Appl. No. 17/932,453.
Application 17/932,453 is a continuation of application No. 17/753,721, previously published as PCT/US2020/050565, filed on Sep. 11, 2020.
Claims priority of provisional application 62/900,060, filed on Sep. 13, 2019.
Claims priority of provisional application 63/044,288, filed on Jun. 25, 2020.
Prior Publication US 2023/0017743 A1, Jan. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/0048 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01)] 27 Claims
 
1. A composition suitable for intravitreal administration, comprising methotrexate at a concentration of about 7 mg/mL to about 9 mg/mL; sucrose at a concentration of about 7% w/v to about 12% w/v; and a phosphate buffer, wherein the composition has an administration volume of about 40 μL, about 45 μL, about 50 μL, or about 60 μL.